For people with serious heart rhythm problems, daily life can be filled with fear and uncertainty.
One of the most dangerous conditions is called ventricular tachycardia, a type of abnormal heartbeat that starts in the lower chambers of the heart.
This condition can lead to sudden cardiac death if not controlled.
Many patients with this problem already live with an implanted defibrillator, a small device that can deliver electric shocks to correct the heart rhythm.
While this device can save lives, repeated shocks can be painful, stressful, and greatly reduce a person’s quality of life.
Doctors usually treat this condition with medication or a procedure called catheter ablation, where a thin tube is inserted into the heart to destroy the area causing the abnormal rhythm.
However, for some patients, these treatments no longer work, or they are too risky to continue. This leaves a group of very ill patients with very limited options.
A new study now offers hope for these patients. Researchers across Europe have tested a treatment called stereotactic arrhythmia radioablation, or STAR. This treatment uses highly focused radiation to target the part of the heart that causes the dangerous rhythm. The results of this large study have been published in the European Heart Journal.
The research was carried out by the STOPSTORM consortium, a group led by the University of Kiel and the University Medical Center Schleswig-Holstein in Germany. This is the first large European study to look at how well this treatment works in real patients across many hospitals.
The study included 193 patients from 28 medical centers across Europe. These patients all had severe ventricular tachycardia that did not respond to standard treatments. For many of them, no other options were left.
The results were very encouraging. Among the patients who were followed for at least six months, the number of dangerous heart rhythm episodes dropped by about 80 percent after the treatment. This is a large improvement, especially for patients who had frequent and life-threatening episodes before.
Another important finding was related to the implanted defibrillator. Many patients with ventricular tachycardia receive shocks from this device when their heart rhythm becomes dangerous. These shocks can be very distressing.
After the STAR treatment, about 72 percent of patients who survived for at least six months did not need any shocks from their defibrillator. This suggests a major improvement in both safety and quality of life.
The safety of the treatment was also carefully studied. Out of all 193 patients, only 12 serious side effects were considered possibly related to the treatment. Importantly, there were no deaths caused by the treatment itself.
However, researchers noted that these patients were already very sick, and the overall death rate in this group remained high due to their underlying heart disease.
One of the key advantages of STAR is that it is completely non-invasive. Unlike catheter ablation, there is no need to insert instruments into the body. Instead, patients receive a single session of highly precise radiation, similar to treatments used in cancer care. This makes the procedure less physically demanding and may be safer for fragile patients.
This new approach also brings together different medical fields. Cardiologists, heart rhythm specialists, and radiation experts must work closely to plan and deliver the treatment. This collaboration is helping to create new ways of treating complex heart conditions.
Although the results are promising, researchers say that more work is needed. They want to better understand which patients will benefit the most, how long the effects will last, and whether there are any long-term risks. The STOPSTORM project is continuing to collect data, with more than 350 cases already included.
When reviewing this study, it is clear that it represents an important step forward. The large number of patients and the involvement of many centers across Europe make the findings more reliable than earlier smaller studies. However, this is still an ongoing study, and longer follow-up is needed to fully understand the benefits and risks.
In summary, STAR therapy offers a new option for patients who have run out of other treatments.
It shows that even in very serious cases, new technology can provide meaningful improvements. While it is not yet a final solution, it opens the door to safer and more effective care for people living with life-threatening heart rhythm disorders.
If you care about heart health, please read studies about how eating eggs can help reduce heart disease risk, and Vitamin K2 could help reduce heart disease risk.
For more information about health, please see recent studies that olive oil may help you live longer, and Vitamin C linked to lower risk of heart failure.
